{"task_id": "e979d530fc8fb552", "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf (Part 175/905)", "text": "t improving to look for progression/complications.\n\n--- Page 181 ---\n167\nChest medicine\nTable 4.2 Empirical treatment of pneumonia (check local policy)\nClinical \nsetting\nOrganisms\nAntibiotic (further dosage\ndetails: pp386\u20137)\nCommunity-acquired\nMild not \npreviously \ue057\nCURB 0\u20131\nStreptococcus pneumoniae\nHaemophilus in\ufb02 uenzae\nOral amoxicillin 500mg\u20131g/8h or clarithro-\nmycin 500mg/12h or doxy cycline 200mg \nloading then 100mg/day (initially 5-day \ncourse)\nModerate\nCURB 2\nStreptococcus pneumoniae\nHaemophilus in\ufb02 uenzae\nMycoplasma pneumoniae\nOral amoxicillin 500mg\u20131g/8h + \nclarithromycin 500mg/12h or doxy cycline \n200mg loading then 100mg/12h \nIf IV required: amoxicillin 500mg/8h + \nclarithromycin 500mg/12h (7-day course)\nSevere\nCURB >3\nAs above\nCo-amoxiclav 1 . 2g/8h IV or cephalosporin IV \n(eg cefuroxime 1 . 5g/8h IV) AND clarithromy-\ncin 500mg/12h IV (7 days)\nAdd \ufb02 ucloxacillin \u00b1 rifampicin if Staph sus-\npected; vancomycin (or teicoplanin) if MRSA \nsuspected. Treat for 10d (14\u201321d if Staph, \nLegionella, or Gram \u03a9ve enteric bacteria \nsuspected)\nPanton-Valentine \nLeukocidin-producing \nStaph. aureus (PVL-SA)\nSeek urgent help. Consider adding IV \nlinezolid, clindamycin, and rifampicin\nAtypical\nLegionella pneumophilia\nFluoroquinolone combined with clarithro-\nmycin, or rifampicin, if severe. See p168\nChlamydophila species\nTetracycline\nPneumocystis jirovecii\nHigh-dose co-trimoxazole (pp400\u20131)\nHospital-acquired\nGram-negative bacilli\nPseudomonas\nAnaerobes\nAminoglycoside IV + antipseudomonal \npenicillin IV or 3rd-generation cephalosporin \nIV (p387)\nAspiration\nStreptococcus pneumoniae\nAnaerobes\nCephalosporin IV + metronidazole IV\nNeutropenic patients\nGram-positive cocci\nGram-negative bacilli\nAminoglycoside IV + antipseudomonal peni-\ncillin IV or 3rd-generation cephalosporin IV\nFungi (p177)\nConsider antifungals after 48h\nAt-risk groups:\n\u2022 All adults \u2265 65yrs old.\n\u2022 Chronic heart, liver, renal, or lung conditions.\n\u2022 Diabetes mellitus not controlled by diet.\n\u2022 Immun o sup pression, eg \ue001spleen function, AIDS, or on chemotherapy or prednis-\nolone >20mg/d, cochlear implant, occupation risk (eg welders), CSF \ufb02 uid leaks. \nVaccinate every 5yrs.\nCI: Pregnancy, lactation, \ue000T\u00b0, previous anaphylaxis to vaccine or one of its com-\nponents.\nPneumococcal vaccine", "text_length": 2270, "metadata": {"source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf (Part 175/905)", "type": "chunk", "chunk_index": 174, "total_chunks": 905, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T17:59:52.199343", "document_uuid": "1c4b3c41-9a74-4d3d-ab11-d2a041c9641f", "filename": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf", "category": "medical_pdf", "section": "body", "year": 2017, "outdated": false, "document_id": "1c4b3c41-9a74-4d3d-ab11-d2a041c9641f"}, "created_at": "2025-12-11T17:59:52.201352", "status": "complete", "chunks_added": 2}